fig2

Comparison of p53 and prohibitin expression in the spectrum of hepatitis, cirrhosis, and hepatocellular carcinoma

Figure 2. Comparative expression of p53 (immunohistochemistry, ×200), PHB (immunohistochemistry, ×400) and TUNEL (immunoassay, ×200) by NL, HCV, CIR and HCC. A: absence of p53 expression in NL; B: low expression of p53 in HCV; C: minor expression of p53 in CIR; D: high nuclear and cytoplasmic expression of p53 in HCC; E: slight cytoplasmic expression of PHB in NL; F: augmented cytoplasmic expression of PHB in HCV; G: high cytoplasmic expression of PHB in CIR; H: strong nuclear and cytoplasmic expression of PHB in HCC; I: slight expression of apoptosis in NL; J: increased expression of apoptosis in HCV; K: augmented expression of apoptosis in CIR; L: marked expression of apoptosis in HCC; (M, N, O) comparison of the p53 (M), cytoplasmic and nuclear PHB (N) and TUNEL (O) labeling scores by NL, HCV, CIR and HCC. *P < 0.05 vs. NL; 0P < 0.05 vs. HCV; P < 0.05 vs. CIR. PHB: prohibitin; TUNEL: transferase-mediated dUTP-biotin nick-end labelling; NL: normal liver; CIR: cirrhosis; HCV: hepatitis C virus; HCC: hepatocellular carcinoma

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/